Pyxis Oncology (PYXS) Price & Analysis

Compare

490 Followers

PYXS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.83 - $5.39

Previous CloseN/A

Volume258.73K

Average Volume (3M)785.91K

Market Cap

$132.72M

Enterprise Value-$2.84M

Total Cash (Recent Filing)$88.94M

Total Debt (Recent Filing)$19.46M

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Nov 18, 2025

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding62,018,135

10 Day Avg. Volume772,439

30 Day Avg. Volume785,909

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.02

Enterprise Value/Revenue-0.46

Enterprise Value/Gross Profit-0.88

Enterprise Value/Ebitda0.03

Forecast

1Y Price Target

$6.25

Price Target Upside192.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentPyxis's lead candidate micvotabart pelidotin (micvo) remains on track for a substantive dose expansion update in patients with squamous cell carcinoma of the head & neck.

Financial PerformancePyxis Oncology, Inc. reported milestone revenue of $2.8M, marking a positive financial development compared to no revenues previously.

Strategic PartnershipsA clinical trial collaboration agreement with Merck is in place for a combination therapy in head and neck squamous cell carcinoma, with preliminary data expected from ongoing patient enrollment.

Bears Say

Financial ChallengesThe company reported a net loss of $0.30 per diluted share, which is an improvement but still indicates financial challenges.

Regulatory ChallengesPreliminary data for 2/3L monotherapy in PD-1 and EGFR targeted therapy experienced patients are not expected until the first half of 2026, indicating a delay in the data timeline.

Pyxis Oncology News

Pyxis Oncology initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Pyxis Oncology (PYXS) with a Buy rating and $5 price target The firm believes...

25d ago

PYXS

Pyxis Oncology initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Pyxis Oncology (PYXS) with a Buy rating and $5 price target Published first on...

26d ago

PYXS

Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck Collaboration

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on PYXS stock, giving a Buy rating today....

1M ago

PYXS

Buy Rating for Pyxis Oncology: Promising Prospects for Micvo and Strong Financial Position

In a report released today, Jeffrey La Rosa from Leerink Partners maintained a Buy rating on Pyxis Oncology,...

1M ago

PYXS

Pyxis Oncology Reports Q2 2025 Financial Results

Pyxis Oncology, Inc. ( ($PYXS) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

PYXS

Pyxis Oncology reports Q2 EPS (30c), consensus (35c)

Reports Q2 revenue $2.8M vs. $0 last year. “We are invigorated by the progress we’re making, particularly in...

2M ago

PYXS

Pyxis Oncology Updates Phase 1 Trial Enrollment

Pyxis Oncology ( ($PYXS) ) has issued an update. On July 31, 2025, Pyxis Oncology revised patient enrollment...

2M ago

PYXS

Crescent Biopharma appoints Jan Pinkas as CSO

Crescent Biopharma (CBIO) announced the appointment of Jan Pinkas, Ph.D., as chief scientific officer. Prior to joining Crescent,...

3M ago

CBIO

PYXS

Pyxis Oncology Appoints New Principal Financial Officer

The latest update is out from Pyxis Oncology ( ($PYXS) ). On July 1, 2025, Pyxis Oncology, Inc....

3M ago

PYXS

Pyxis Oncology Elects New Directors at Annual Meeting

Pyxis Oncology ( ($PYXS) ) just unveiled an announcement. On June 18, 2025, Pyxis Oncology, Inc. held its...

3M ago

PYXS

Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments

Pyxis Oncology, Inc. ( ($PYXS) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

PYXS

Promising Developments and Risk-Reward Profile Justify Buy Rating for Pyxis Oncology

Jeffrey La Rosa, an analyst from Leerink Partners, maintained the Buy rating on Pyxis Oncology (PYXS – Research...

4M ago

PYXS

Buy Rating for Pyxis Oncology Driven by Promising Preclinical Data and Upcoming Clinical Updates

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Pyxis Oncology (PYXS – Research Report) today and...

4M ago

PYXS

Pyxis Oncology Reports Q1 Loss and Business Update

Pyxis Oncology ( ($PYXS) ) has shared an announcement. On May 15, 2025, Pyxis Oncology reported its first-quarter...

5M ago

PYXS

PYXS FAQ

What was Pyxis Oncology’s price range in the past 12 months?

Pyxis Oncology lowest stock price was $0.83 and its highest was $5.39 in the past 12 months.

What is Pyxis Oncology’s market cap?

Pyxis Oncology’s market cap is $132.72M.

When is Pyxis Oncology’s upcoming earnings report date?

Pyxis Oncology’s upcoming earnings report date is Nov 18, 2025 which is in 50 days.

How were Pyxis Oncology’s earnings last quarter?

Pyxis Oncology released its earnings results on Aug 14, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.352 by $0.052.

Is Pyxis Oncology overvalued?

According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pyxis Oncology pay dividends?

Pyxis Oncology does not currently pay dividends.

What is Pyxis Oncology’s EPS estimate?

Pyxis Oncology’s EPS estimate is -0.34.

How many shares outstanding does Pyxis Oncology have?

Pyxis Oncology has 62,018,135 shares outstanding.

What happened to Pyxis Oncology’s price movement after its last earnings report?

Pyxis Oncology reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.352. Following the earnings report the stock price went up 8.85%.

Which hedge fund is a major shareholder of Pyxis Oncology?

Currently, no hedge funds are holding shares in PYXS

Pyxis Oncology Stock Smart Score

Outperform

Fundamentals

Return on Equity

-74.80%

Trailing 12-Months

Asset Growth

-40.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pyxis Oncology

Pyxis Oncology, Inc. (PYXS) is a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer. The company operates within the healthcare sector, primarily targeting oncology as its core field. Pyxis Oncology aims to address unmet medical needs by leveraging its proprietary platforms to discover and develop innovative therapies that improve patient outcomes.

Pyxis Oncology (PYXS) Earnings & Revenues

Historic Earnings Reports

PYXS Stock 12 Month Forecast

Average Price Target

$6.25

▲(192.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.33,1.8430769230769233,2.3561538461538465,2.8692307692307693,3.3823076923076925,3.8953846153846157,4.408461538461538,4.921538461538462,5.434615384615385,5.947692307692308,6.460769230769231,6.9738461538461545,7.486923076923077,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.33,1.7084615384615385,2.086923076923077,2.4653846153846155,2.8438461538461537,3.2223076923076923,3.600769230769231,3.979230769230769,4.357692307692307,4.736153846153846,5.114615384615385,5.493076923076923,5.871538461538462,{"y":6.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.33,1.6123076923076924,1.8946153846153848,2.176923076923077,2.4592307692307696,2.741538461538462,3.023846153846154,3.306153846153846,3.5884615384615386,3.870769230769231,4.153076923076924,4.435384615384615,4.717692307692308,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >